[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]
Fırat Tıp Dergisi
2019, Cilt 24, Sayı 2, Sayfa(lar) 089-096
[ Turkish ] [ Tam Metin ] [ PDF ]
The Rates of Coexistence Metastases in Patients with Advanced Prostate Cancer in 68Ga-PSMA PET/CT: A Retrospective Analysis
Halil KÖMEK1, Tansel Ansal BALCI2
1Sağlık Bilimleri Üniversitesi Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Nükleer Tıp Kliniği, Diyarbakır, Türkiye
2Fırat Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Elazığ, Türkiye

Objective: To determine the rate of metastasis and coexistence metastases in patients with advanced prostate cancer in gallium 68 -prostate specific membrane antigen PET/CT (68Ga-PSMA PET/CT).

Material and Method: A total of 234 consecutive patients with advanced prostate cancer who underwent 68Ga-PSMA PET/CT were included in this retrospective study. Data on previous treatments, Gleason score, serum Prostate Specific Antigen (PSA) levels (ng/mL) and 68Ga-PSMA PET/CT findings were recorded.

Results: The mean age of the patients was 67.6 ± 8.5 years. Median PSA level was 21.7 (0.2-880) ng/ml. Pelvic (41%) and abdominal (30.3%) lymph nodes were the most commonly involved lymph nodes, while bone metastases were multimetastatic and bone carcinomatosis in 22.2% and 30.6% of patients, respectively. Other common distant organ metastases were lung (7.6%) and liver (7.2%) metastases. Level 1-4 lymph node positivity was noted in 29.4%, 33.3% and 6.8% of patients with liver metastasis, lung metastasis and seminal vesicle invasion, respectively. Concomitant lung metastasis was evident in 41.1% of patients with liver metastasis, while lung or liver metastasis was evident in 13.6% of patients with seminal vesicle invasion. Bone metastasis was evident in all patients with liver and lung metastasis, and in 65.9% of patients with seminal vesicle invasion.

Conclusion:The findings of this study showed the value of 68Ga-PSMA PET/CT in detecting coexistence rate of metastases in advanced prostate cancer.


[ Turkish ] [ Tam Metin ] [ PDF ]
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]